• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Livongo Health and Abbott Partner to Offer Continuous Glucose Monitoring Insights

by Jasmine Pennic 09/05/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Livongo Health Raises $52.5M to Expand Diabetes Management to International Markets

Livongo Health, a consumer digital health company empowering people with chronic conditions to live better and healthier lives, today announced that it will be the first comprehensive offering for people with diabetes to integrate continuous glucose data from Abbott’s FreeStyle® Libre Pro System, a revolutionary continuous glucose monitoring (CGM) system for healthcare professionals.

Through this integration collaboration, Livongo will offer, where appropriate and prescribed, the FreeStyle Libre Pro System to its members with diabetes. This will provide members with a visual snapshot of their glucose data, known as the Ambulatory Glucose Profile (AGP), offering a clearer overview of not only glucose levels but also patterns and trends within those levels. Members also may request the AGP be shared with their personal physicians. This information allows doctors and people with diabetes to make better, personal treatment decisions.

Livongo for Diabetes drives behavior change through a combination of consumer health technology, personalized recommendations and real-time support at the point of impact. 

In order to start using the system, a healthcare professional will apply the FreeStyle Libre Pro sensor on the back of the Livongo members’ upper arm. The sensor will remain in place for up to 14 days, continuously measuring glucose in interstitial fluid and recording glucose levels every 15 minutes – capturing a complete glycemic profile that informs the AGP.

In the USA, 1 in 11 people has diabetes, costing the healthcare system more than $150 billion annually. For these individuals, maintaining blood glucose in the normal range (80–180 mg/dL) is a critical part of reducing emergency department visits, hospitalizations, renal failure and other costly complications of diabetes. A recent survey of 1,527 people with type 2 diabetes found that 40 percent do not test glucose levels as frequently as recommended by their health-care professionals.

 

“Incorporating glucose data from the FreeStyle Libre Pro will enhance the Livongo member experience by providing personalized insights to influence behavior,” said Dr. Jennifer Schneider, Chief Medical Officer at Livongo. “Teaming up with Abbott supports our efforts to leverage valuable data across the healthcare ecosystem so that our members receive the right information, tools, and support when they need it most.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Continuous Glucose Monitoring (CGM), Diabetes Management, Diabetes Management Platform, Livongo Health, Type 2 Diabetes

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Kinetik CEO Sufian Chowdhury on Fighting NEMT Fraud & Waste

Most-Read

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

WeightWatchers Files for Bankruptcy to Eliminate $1.15B in Debt

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

KLAS: Epic Dominates 2024 EHR Market Share Amid Focus on Vendor Partnership; Oracle Health Sees Losses Despite Tech Advances

'Cranky Index' Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

‘Cranky Index’ Reveals EHR Alert Frustration Peaks Midweek, Highest Among Admin Staff

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Madison Dearborn Partners to Acquire Significant Stake in NextGen Healthcare

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Wandercraft Begins Clinical Trials for Physical AI-Powered Personal Exoskeleton

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Chipiron Secures $17M to Transform MRI Access with Portable Scanner

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Abbott to Integrate FreeStyle Libre Glucose Data with Epic EHR

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |